Balanced news tone
News Sentiment
ALMR sentiment intelligence
Alamar Biosciences, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
42 relevant articles
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
+9.6% over one week, +29.2% over four weeks, trend inactive, and near fair-value range.
Alamar Biosciences Sets Aug. 10 Results Webcast; Replay to Follow
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
80/100 classification
One-week reaction
9.6%
Price confirming higher
Trend fit
Trend inactive
29.2% over four weeks
Fair value
21.5%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
4
Neutral
37
Negative
1
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Stock Titan
Direct company coverage
Alamar Biosciences Sets Aug. 10 Results Webcast; Replay to Follow
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 20:11
- Source
- Stock Titan
GlobeNewswire
Direct company coverage
Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 20:05
- Source
- GlobeNewswire
Market source
Industry context
Reflecting On Medical Devices & Supplies - Specialty Stocks’ Q1 Earnings: Integer Holdings (NYSE:ITGR)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 18:07
- Source
- Market source
Trefis
Direct company coverage
Alamar Hits A High Note On Alzheimer’s Buzz
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 21:02
- Source
- Trefis
Trefis
Direct company coverage
Alamar Hits A High Note On Alzheimer's Buzz
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 20:50
- Source
- Trefis
TradingView
Direct company coverage
Alamar Biosciences, Inc. Stock 12‑Month Price Target Raised to $30.6, Implies 8% Upside
- Tone
- Positive 80/100
- Event
- Analyst action
- Published
- 13 Jul 2026 13:20
- Source
- TradingView
MT Newswires
Direct company coverage
Alamar Biosciences Partners With Research Universities on Neurodegenerative Biomarker Project
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 07:56
- Source
- MT Newswires
GlobeNewswire
Direct company coverage
Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 06:30
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 10:11
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Sands Capital reports 6.1% Alamar Biosciences (ALMR) stake and board change
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 07 Jul 2026 20:55
- Source
- Stock Titan
GlobeNewswire
Direct company coverage
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 13:12
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Alamar puts Alzheimer’s tau tangle test into blood panels
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 07:00
- Source
- Stock Titan
TradingView
Direct company coverage
Price to sales forward of Alamar Biosciences, Inc. – NASDAQ:ALMR
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 11:45
- Source
- TradingView
Stock Titan
Direct company coverage
Sherpa Funds Hold 7.2% of Alamar Biosciences (NASDAQ: ALMR)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 07:00
- Source
- Stock Titan
Barron's
Direct company coverage
This Undervalued Medical-Devices Stock Is Poised for a Rebound
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Barron's
Market source
Industry context
Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jun 2026 07:00
- Source
- Market source
GlobeNewswire
Direct company coverage
Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 18:43
- Source
- GlobeNewswire
eciks.org
Direct company coverage
UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+
- Tone
- Positive 84/100
- Event
- Earnings
- Published
- 26 May 2026 07:00
- Source
- eciks.org
Market source
Industry context
Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 22 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Evaluating Alamar Biosciences (ALMR) Valuation As Shares Show Modest Year To Date Gains
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 May 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
Fresh off a $220M IPO, Alamar expands neuro tests and posts $26M quarter
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 08 May 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
Alamar Biosciences (NASDAQ: ALMR) grows Q1 sales but widens loss
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- Stock Titan
StockStory
Industry context
Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 May 2026 07:00
- Source
- StockStory
StockStory
Direct company coverage
GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 07:00
- Source
- StockStory
Market source
Industry context
Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Apr 2026 07:00
- Source
- Market source
Seeking Alpha
Direct company coverage
Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 22 Apr 2026 07:00
- Source
- Seeking Alpha
The Manila Times
Direct company coverage
Alamar Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Apr 2026 07:00
- Source
- The Manila Times
Barchart.com
Direct company coverage
Cathie Wood Is Buying Up Alamar Biosciences Stock After Its IPO. Should You Snag Proteomics-Focused ALMR Too?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Apr 2026 07:00
- Source
- Barchart.com
Seeking Alpha
Direct company coverage
Alamar Biosciences: Looking For An Early Detection
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Apr 2026 07:00
- Source
- Seeking Alpha
Market source
Direct company coverage
Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Apr 2026 07:00
- Source
- Market source